Clinical Guidelines Alert November 2023 Banner
  • Neonatal Resuscitation
    • Author:American Heart Association (AHA); American Academy of Pediatrics (AAP)
    • Published:November 16, 2023
FDA Drug Approvals November 2023 Banner
  • Keytruda (Merck) New Indication
    • In combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
  • Voquezna (Phathom Pharmaceuticals) 
    • For healing and to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults.
  • Zituvimet (Zydus Lifesciences) 
    • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Zepbound (Eli Lilly)
    • For chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter (kg/ m2) or greater) or overweight (body mass index of 27 kg/m2 or greater) with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity.
  • Fruzaqla (Takeda) 
    • For adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
  • Adzynma (Takeda)
    • For prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).
  • Ixchiq (Valneva) 
    • For individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus.
  • Exparel (Pacira)Expanded Indication
    • For use in adult patients as an adductor canal block and a sciatic nerve block in the popliteal fossa.
  • Augtyro (Bristol Myers Squibb) 
    • Treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
  • DefenCath (CorMedix)
    • To reduce the incidence of catheter-related bloodstream infections (CRBSIs) for the limited population of adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC).
  • Keytruda (Merck)New Indication
    • With fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of adult patients with locally advanced unresectable or metastatic, human epidermal growth factor receptor (HER2)–negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • Truqap (AstraZeneca)
    • With fulvestrant for certain previously treated adults with hormone receptor (HR)–positive, human epidermal growth factor receptor (HER2)–negative, locally advanced or metastatic breast cancer.
  • Xtandi (Astellas / Pfizer) Expanded Indication
    • For men with nonmetastatic castration-sensitive prostate cancer who experience biochemical recurrence and are at high risk for metastasis.
  • Ryzneuta (Evive Biotech)
    • To decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
  • Ogsiveo (SpringWorks Therapeutics) 
    • Treatment of adult patients with progressing desmoid tumors who require systemic treatment.

Copyright © 2023 Guideline Central, All rights reserved.